SG
SPRB

StoneX Group’s Spruce Biosciences SPRB Stock Holding History

StoneX Group’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-134
Closed -$13.8K – 641
2022
Q3 		$13.8K Sell
134
-25
-16% -$3.49K ﹤0.01% 293
2022
Q2 		$20.7K Buy
+159
New +$20.4K ﹤0.01% 434

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

StoneX Group's SPRB Position: Q4 2022 in Review

StoneX Group sold out of Spruce Biosciences (SPRB) in Q4 2022, closing a stake of 134 shares — an estimated $13.8K sold.

StoneX Group first reported a position in SPRB in Q2 2022 and held it in 2 quarters. The position peaked at $20.7K in Q2 2022. 29 funds tracked by Wall St. Rank hold SPRB as of Q4 2022.

  • StoneX Group reported no remaining Spruce Biosciences position as of Q4 2022 after selling out during the quarter.
  • StoneX Group sold 134 Spruce Biosciences shares in Q4 2022, an estimated $13.8K.
  • StoneX Group first reported a position in Spruce Biosciences in Q2 2022 and held it in 2 quarters.
  • StoneX Group's Spruce Biosciences position peaked at $20.7K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.